Deramiocel heart-derived cellular therapy in advanced Duchenne muscular dystrophy (HOPE-3): a phase 3, randomised, double-blind, placebo-controlled trial

Coverage (5)

• FDA panel votes against Capricor's Duchenne heart disease therapy Reuters · 13h ago
• The Lancet Publishes HOPE-3 Data for Capricor Therapeutics’ Deramiocel in Duchenne Muscular Dystrophy finance.yahoo.com · 13h ago
• FDA adcomm shoots down Capricor's Duchenne cell therapy after meeting marked by statistical dispute Fierce Biotech · 13h ago
• FDA expert panel recommends against approval of Capricor’s Duchenne drug STAT · 13h ago
• Deramiocel heart-derived cellular therapy in advanced Duchenne muscular dystrophy (HOPE-3): a phase 3, randomised, double-blind, placebo-controlled trial The Lancet · 13h ago

The coverage curve

How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →

Related trends